CN118202046A - 具有降低的脱靶效应的经修饰的小干扰rna分子 - Google Patents
具有降低的脱靶效应的经修饰的小干扰rna分子 Download PDFInfo
- Publication number
- CN118202046A CN118202046A CN202280051993.8A CN202280051993A CN118202046A CN 118202046 A CN118202046 A CN 118202046A CN 202280051993 A CN202280051993 A CN 202280051993A CN 118202046 A CN118202046 A CN 118202046A
- Authority
- CN
- China
- Prior art keywords
- nucleotides
- disease
- interfering rna
- modified sirna
- antisense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021107862 | 2021-07-22 | ||
| CNPCT/CN2021/107862 | 2021-07-22 | ||
| PCT/CN2022/107028 WO2023001234A1 (en) | 2021-07-22 | 2022-07-21 | Modified small interfering rna molecules with reduced off-target effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118202046A true CN118202046A (zh) | 2024-06-14 |
Family
ID=84979733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280051993.8A Pending CN118202046A (zh) | 2021-07-22 | 2022-07-21 | 具有降低的脱靶效应的经修饰的小干扰rna分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240425853A1 (https=) |
| EP (1) | EP4373932A1 (https=) |
| JP (1) | JP2024529930A (https=) |
| KR (1) | KR20240042457A (https=) |
| CN (1) | CN118202046A (https=) |
| CA (1) | CA3227144A1 (https=) |
| WO (1) | WO2023001234A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080188430A1 (en) * | 2001-05-18 | 2008-08-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
| WO2005035759A2 (en) * | 2003-08-20 | 2005-04-21 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2005032486A2 (en) * | 2003-10-02 | 2005-04-14 | Duke University | A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY |
| EP3889261A1 (en) * | 2007-08-27 | 2021-10-06 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| CN106117289B (zh) * | 2016-06-24 | 2019-02-12 | 郑州大学 | 2’-o-moe-3’-h-硫代磷酸酯核苷单体及其合成方法 |
| CN110540990B (zh) * | 2019-07-16 | 2024-08-20 | 武汉泽智生物医药有限公司 | 沉默小眼畸形转录因子mRNA表达的siRNA分子 |
-
2022
- 2022-07-21 CN CN202280051993.8A patent/CN118202046A/zh active Pending
- 2022-07-21 KR KR1020247006025A patent/KR20240042457A/ko active Pending
- 2022-07-21 CA CA3227144A patent/CA3227144A1/en active Pending
- 2022-07-21 WO PCT/CN2022/107028 patent/WO2023001234A1/en not_active Ceased
- 2022-07-21 EP EP22845398.1A patent/EP4373932A1/en active Pending
- 2022-07-21 JP JP2024503797A patent/JP2024529930A/ja active Pending
- 2022-07-21 US US18/580,688 patent/US20240425853A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240042457A (ko) | 2024-04-02 |
| EP4373932A1 (en) | 2024-05-29 |
| US20240425853A1 (en) | 2024-12-26 |
| CA3227144A1 (en) | 2023-01-26 |
| WO2023001234A9 (en) | 2023-03-02 |
| WO2023001234A1 (en) | 2023-01-26 |
| JP2024529930A (ja) | 2024-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2805086C (en) | Antisense modulation of interleukins 17 and 23 signaling | |
| WO2023098908A1 (en) | Modification patterns for small interfering rna molecules with high stability and gene silencing activities | |
| CN114729360A (zh) | 降低病毒分子水平的方法 | |
| TW201730341A (zh) | 抑制補體b因子之表現之反義寡核苷酸 | |
| WO2022117085A1 (en) | Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19 | |
| WO2023001234A1 (en) | Modified small interfering rna molecules with reduced off-target effects | |
| WO2026026776A1 (zh) | 抑制APP基因表达的siRNA及其缀合物和应用 | |
| WO2026001832A1 (zh) | 核酸在制备防治恶液质的药物中的应用和施用方法 | |
| CN118086310B (zh) | 一种用于抑制circATF7IP基因表达的siRNA、递送系统及应用 | |
| WO2026067447A1 (en) | Small Interfering RNAs Targeting ANT2 and Uses Thereof for Disease Treatment | |
| WO2022109022A1 (en) | Rna-targeting splicing modifiers for treatment of mda5-associated conditions and diseases | |
| WO2017022650A1 (ja) | 修飾siRNA及びそれを含む医薬組成物 | |
| CN112654706B (zh) | 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途 | |
| EP4678747A2 (en) | Double-stranded rnai agents for targeting and regulating hbv gene expression, and a use thereof | |
| WO2024169577A1 (zh) | 用于抑制fxii基因表达的双链核糖核酸及其修饰物、缀合物和用途 | |
| WO2025026124A1 (zh) | C4b基因抑制剂组合物及其应用 | |
| WO2025103457A1 (zh) | 抑制LPA表达的siRNA及其用途 | |
| WO2024182585A1 (en) | Cancer therapy with tgf-beta-2 and irinotecan agents | |
| WO2022206819A1 (zh) | 一种用于治疗亨廷顿病的rna递送系统 | |
| WO2026026715A1 (zh) | 一种用于抑制KRAS基因表达的siRNA及其修饰物与应用 | |
| CN114958839A (zh) | 抑制肌肉瘤细胞中FOXO1基因表达的siRNA序列及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |